ProCE Banner Activity

PEP-in-Pocket for HIV Prevention in Canada

Clinical Thought

PEP-in-pocket has the potential to expand HIV prevention coverage in a timely manner for patients with infrequent or unplanned HIV exposures. Use of dynamic choice HIV prevention, where individuals can select between PrEP and PEP, may allow for increased HIV prevention coverage and patient autonomy, as demonstrated in studies completed in Africa.

Released: March 07, 2023

Expiration: March 05, 2024

Share

Supporters

This activity is supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

Merck & Co., Inc.

ViiV Healthcare

Disclosure

Darrell Tan, MD, FRCPC, PhD: researcher: AbbVie, Gilead, GlaxoSmithKline.